EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
نویسندگان
چکیده
EPR (electron paramagnetic resonance) has been used to study interactions of the Ru(III) anticancer compounds imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and indazolium [trans-RuCl4(1H-indazole)2] (KP1019) with isolated subcellular components and whole cells of the yeast Saccharomyces cerevisiae. These studies are the first to probe the intracellular speciation of ruthenium using the EPR technique. Initially, NAMI-A and KP1019 were incubated at 30 °C, for time periods up to 24 hours with isolated cell wall, mitochondrial, cytoplasmic, and nuclear fractions of S. cerevisiae. EPR measurements demonstrate that NAMI-A initially forms non-coordinate interactions with each cell component. After longer incubation times these are replaced by coordinated species, particularly with cytoplasmic proteins. KP1019 shows a greater tendency to coordinate directly with cell components, demonstrating significant interactions with mitochondria and cytoplasmic proteins. Subsequently, each complex was incubated with whole cells of S. cerevisiae at 30 °C and whole-cell EPR measurements detected Ru(III) species in measurable concentrations even after 24 hours of incubation. Analysis of the resulting EPR spectra suggests NAMI-A interacts predominantly with cell walls, while KP1019 was found to be coordinating with both the mitochondrial and cytoplasmic protein fractions. Comparison of the signal intensity of these data with those from incubation with whole cells at 4 °C indicates different modes of transmembrane transport for each complex. These studies demonstrate that EPR can provide valuable insight into the oxidation state and speciation of ruthenium compounds in cellular environments.
منابع مشابه
Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.
The ruthenium anticancer compound NAMI-A, imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)], is currently undergoing advanced clinical evaluation. As with other Ru(iii) chemotherapeutic candidates, interactions with human serum albumin (HSA) have been identified as a key component of the speciation of NAMI-A following intravenous administration. To characterize coordination to HSA, we have perfor...
متن کاملMetallomics for drug development: a further insight into intracellular activation chemistry of a ruthenium(III)-based anticancer drug gained using a multidimensional analytical approach.
The mechanism by which the most relevant ruthenium anticancer drugs are activated in tumors to commence their tumor-inhibiting action remains one of the challenging research tasks of present-day metallomics. This contribution aims to capture and identify eventually more reactive species of one of two bis-indazole tetrachloridoruthenate(III) compounds that are progressing in clinical trials. In ...
متن کاملRuthenium(II / III) bipyridine complexes incorporating thiol-based imine functions Synthesis, spectroscopic and redox properties
II 1 A group of five new ruthenium(II) bipyridine heterochelates of the type [Ru (bpy) L] 1a–1e have been synthesized (bpy52,292 bipyridine; L5anionic form of the thiol-based imine ligands, HS–C H N=C(H)C H (R) (R5OMe, Me, H, Cl, NO ). The complexes 6 4 6 4 2 1a21e are 1:1 conducting and diamagnetic. The complexes 1a21e exhibit strong MLCT transitions in the visible region and intra-ligand tran...
متن کاملA shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells.
The study reported herein focused on the development and optimization of a versatile analytical methodology for characterization of intracellular distribution of protein-bound species of ruthenium originating from an anticancer Ru-based drug, indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]. A direct analysis of the drug-treated cytosol of cancer cells using size-exclusion chromat...
متن کاملOrganoruthenium Anticancer Agents: Scope and Reactivity
Organometallic compounds have emerged as attractive scaffolds for drug development due to the reactivity that is intrinsic to metal centers and ligand variability leads to several geometries. 2 Cisplatin, PtCl2(NH3)2, and related platinum based drugs have been extensively used as anti-cancer treatments and are highly effective, but suffer from several problems: some cancer lines are resistant t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Metallomics : integrated biometal science
دوره 5 12 شماره
صفحات -
تاریخ انتشار 2013